SOPHiA GENETICS (SOPH) Competitors $3.68 0.00 (0.00%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$3.70 +0.02 (+0.68%) As of 03/27/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SOPH vs. COGT, OCS, CDMO, PRAX, AVXL, XERS, QURE, CMRX, ABCL, and PRTAShould you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Cogent Biosciences (COGT), Oculis (OCS), Avid Bioservices (CDMO), Praxis Precision Medicines (PRAX), Anavex Life Sciences (AVXL), Xeris Biopharma (XERS), uniQure (QURE), Chimerix (CMRX), AbCellera Biologics (ABCL), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry. SOPHiA GENETICS vs. Cogent Biosciences Oculis Avid Bioservices Praxis Precision Medicines Anavex Life Sciences Xeris Biopharma uniQure Chimerix AbCellera Biologics Prothena Cogent Biosciences (NASDAQ:COGT) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations. Do institutionals & insiders believe in COGT or SOPH? 31.6% of SOPHiA GENETICS shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to COGT or SOPH? In the previous week, Cogent Biosciences had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 4 mentions for Cogent Biosciences and 2 mentions for SOPHiA GENETICS. Cogent Biosciences' average media sentiment score of 1.05 beat SOPHiA GENETICS's score of 0.97 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Overall Sentiment Cogent Biosciences Positive SOPHiA GENETICS Positive Is COGT or SOPH more profitable? Cogent Biosciences has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -110.71%. SOPHiA GENETICS's return on equity of -55.06% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -112.55% -60.44% SOPHiA GENETICS -110.71%-55.06%-38.33% Which has preferable valuation and earnings, COGT or SOPH? SOPHiA GENETICS has higher revenue and earnings than Cogent Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$192.41M-$1.94-3.41SOPHiA GENETICS$65.17M3.77-$78.98M-$0.95-3.87 Which has more volatility and risk, COGT or SOPH? Cogent Biosciences has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Does the MarketBeat Community prefer COGT or SOPH? Cogent Biosciences received 271 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 70.37% of users gave SOPHiA GENETICS an outperform vote while only 70.22% of users gave Cogent Biosciences an outperform vote. CompanyUnderperformOutperformCogent BiosciencesOutperform Votes29070.22% Underperform Votes12329.78% SOPHiA GENETICSOutperform Votes1970.37% Underperform Votes829.63% Do analysts recommend COGT or SOPH? Cogent Biosciences presently has a consensus target price of $14.43, indicating a potential upside of 118.28%. SOPHiA GENETICS has a consensus target price of $6.80, indicating a potential upside of 84.78%. Given Cogent Biosciences' higher possible upside, equities analysts plainly believe Cogent Biosciences is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryCogent Biosciences beats SOPHiA GENETICS on 10 of the 17 factors compared between the two stocks. Remove Ads Get SOPHiA GENETICS News Delivered to You Automatically Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SOPH vs. The Competition Export to ExcelMetricSOPHiA GENETICSBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$245.41M$3.04B$5.64B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-3.3829.2923.1319.03Price / Sales3.77436.17383.8993.17Price / CashN/A168.6838.1634.64Price / BookN/A3.956.944.33Net Income-$78.98M-$71.95M$3.20B$247.06M7 Day Performance21.85%-3.76%-2.33%-0.37%1 Month Performance0.27%-10.33%2.84%-3.85%1 Year Performance-25.35%-27.15%10.75%1.27% SOPHiA GENETICS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SOPHSOPHiA GENETICS2.6708 of 5 stars$3.68flat$6.80+84.8%-30.0%$245.41M$65.17M-3.38520Short Interest ↓COGTCogent Biosciences2.4137 of 5 stars$7.39+3.5%$14.43+95.2%+1.4%$841.35MN/A-2.9880Positive NewsOCSOculis1.9889 of 5 stars$18.83+0.3%$29.50+56.7%+62.9%$822.16M$980,000.00-9.762Short Interest ↑CDMOAvid Bioservices1.0299 of 5 stars$12.50+0.1%$12.25-2.0%+79.0%$799.18M$139.91M-5.23320High Trading VolumePRAXPraxis Precision Medicines2.5431 of 5 stars$38.93+1.7%$123.80+218.0%-34.4%$784.95M$8.55M-3.78110Positive NewsAVXLAnavex Life Sciences3.7863 of 5 stars$9.20-2.4%$44.00+378.3%+88.5%$782.59MN/A-16.7340Positive NewsXERSXeris Biopharma3.2728 of 5 stars$5.03+4.4%$5.92+17.6%+176.0%$774.32M$203.07M-11.18290High Trading VolumeQUREuniQure2.6975 of 5 stars$14.53+2.3%$38.89+167.6%+142.7%$767.89M$27.12M-2.93500CMRXChimerix3.5537 of 5 stars$8.47+0.1%$8.53+0.7%+741.6%$761.76M$159,000.00-9.0190Earnings ReportShort Interest ↓ABCLAbCellera Biologics2.4747 of 5 stars$2.54+0.8%$7.00+175.6%-47.4%$756.89M$28.83M-4.16500Positive NewsPRTAProthena3.3429 of 5 stars$13.74flat$55.00+300.3%-48.3%$739.58M$135.16M-5.97130Analyst RevisionNews CoveragePositive News Remove Ads Related Companies and Tools Related Companies COGT Alternatives OCS Alternatives CDMO Alternatives PRAX Alternatives AVXL Alternatives XERS Alternatives QURE Alternatives CMRX Alternatives ABCL Alternatives PRTA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SOPH) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SOPH Stock Free SOPH Stock Alerts